Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine, Dexamethasone, LMWH, and 5-FU in Proliferative Vitreoretinopathy
NCT00370760Phase 3Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colchicine, dexamethasone, low molecular weight heparin calcium and fluorouracil in Proliferative Vitreoretinopathy (PVR), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Retinal reattachment rate at 6 months. Status: unknown.
02
Drugs
colchicinedexamethasonelow molecular weight heparin calciumfluorouracil
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT00370760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00370760.